A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-10
DOI
10.1038/s41598-019-43652-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
- (2018) Scott H. Donaldson et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy
- (2017) Gautham Marigowda et al. Journal of Cystic Fibrosis
- Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease
- (2017) Dominique Hubert et al. Journal of Cystic Fibrosis
- Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
- (2017) Steven M. Rowe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
- (2017) Jennifer L. Taylor-Cousar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial
- (2017) Felix Ratjen et al. Lancet Respiratory Medicine
- Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study
- (2017) Michael W Konstan et al. Lancet Respiratory Medicine
- New and emerging targeted therapies for cystic fibrosis
- (2016) Bradley S Quon et al. BMJ-British Medical Journal
- New and emerging targeted therapies for cystic fibrosis
- (2016) Bradley S Quon et al. BMJ-British Medical Journal
- Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
- (2016) Jane C Davies et al. Lancet Respiratory Medicine
- Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis
- (2016) J Stuart Elborn et al. Lancet Respiratory Medicine
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
- (2015) Claire E. Wainwright et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial
- (2015) Richard B Moss et al. Lancet Respiratory Medicine
- Gene therapy in cystic fibrosis
- (2014) D. K. Armstrong et al. ARCHIVES OF DISEASE IN CHILDHOOD
- Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis
- (2014) Penny Whiting et al. HEALTH TECHNOLOGY ASSESSMENT
- Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Eitan Kerem et al. Lancet Respiratory Medicine
- A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
- (2014) Michael P Boyle et al. Lancet Respiratory Medicine
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)
- (2014) Edward F McKone et al. Lancet Respiratory Medicine
- Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with aG551DMutation
- (2013) Jane C. Davies et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
- (2012) Patrick A. Flume et al. CHEST
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation
- (2011) Bonnie W. Ramsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
- (2011) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for theF508del-CFTRmutation
- (2011) J P Clancy et al. THORAX
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation
- (2010) Frank J. Accurso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
- (2009) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started